摘要
糖尿病肾病(diabetic kidney disease,DKD)是糖尿病患者进展为终末期肾脏疾病的主要原因,中医药能够明显改善DKD患者的临床症状、改善肾功能、延缓疾病进展,且具有不良反应少、多靶点多途径治疗等优势,常用治疗方法有:中医药方剂治疗、中成药治疗、中药注射液治疗、中医外治法及中西医结合治疗等。但目前的研究尚有以下不足,首先没有明确证型分类及规范分期,治疗方案也没有统一的标准。其次,虽有大量临床研究、基础研究表明中医药对于特定分期及证型确有疗效,但样本量较小,且没有统一研究标准,对于DKD的整体疗效还有待进一步研究,且重复研究较多,缺乏循证依据及远期疗效评价。因此,以后的研究应深入探讨中医药治疗DKD的作用机制,细化辨证分型,开展多中心大样本的临床试验,进行循证医学研究和中医药处方的标准化研究,建立早期危险因素的预测评估系统,建立统一规范化的临床疗效评价体系,通过生物信息学及临床试验优化处方。
Diabetes kidney disease(DKD)is the main reason for diabetes patients to progress to end-stage renal disease.TCM can significantly improve the clinical symptoms of DKD patients,improve renal function,delay disease progression,and has the advantages of significant efficacy,fewer adverse reactions,multiple targets and multiple ways.Common treatment methods include TCM formula treatment,Chinese patent medicine treatment,treatment with Chinese medicinal injection,external treatment of TCM,integrated traditional Chinese and Western medicine treatment,etc.However,current research still has the following shortcomings:Firstly,there is no clear classification of syndrome types and standardized staging,and there is no unified standard for treatment plans.Secondly,although there are numerous clinical and basic studies indicating that TCM has therapeutic effects on specific stages and syndromes,the sample size is small and there is no unified research standard.Further research is needed on the overall efficacy of DKD.And there are many repeated studies,lacking evidence-based basis and long-term efficacy evaluation.Therefore,future research should deeply investigate the mechanism of action of TCM in treating DKD,refine syndrome differentiation and classification,conduct clinical trials with multiple centers and large samples,carry out evidence-based medicine research and standardization of TCM formulas,establish a prediction and evaluation system for early risk factors,and a unified and standardized clinical efficacy evaluation system,and optimize formulas through bioinformatics and clinical trials.
作者
王帆竞
林逸轩
赵进东
申国明
方朝晖
WANG Fan-jing;LIN Yi-xuan;HAO Jin-dong;SHEN Guo-ming;FANG Chao-hui(The First Affiliated Hospital of Anhui University of Chinese Medicine,Hefei,Anhui,China,230031;Diabetes Research Institute of Anhui Academy of Chinese Medicine,Hefei,Anhui,China,230031;Anhui University of Chinese Medicine,Hefei,Anhui,China,230031;Xin'an Key Laboratory of Medical Science ofMinistry of Education,Hefei,Anhui,China,230031)
出处
《河南中医》
2023年第6期933-939,共7页
Henan Traditional Chinese Medicine
基金
国家自然科学基金项目(8217140926,81774286,81573944)
国家中医临床研究基地业务建设第二批科研专项项目(JDZX2015123)
国家重点研发计划“中医药现代化研究”重点专项项目(2018YFC1704202,2020YFE0201800)
安徽高校自然科学研究项目(KJ2020A0401)
安徽高校协同创新项目(GXXT-2020-025)。
关键词
糖尿病肾病
中成药
中药注射液
中医外治法
中西医结合
diabetic kidney disease(DKD)
Chinese patent
Chinese medicinal injection
external of TCM
integrated traditional Chinese and Western medicine
作者简介
王帆竞(1995-),女,安徽合肥人,硕士研究生;通信作者:方朝晖,E-mail:fangzhaohuil111@163.com。
